PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Nevro Corp.

USPTO PatentsView assignee record - 152 granted patents across 12 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

Explore the portfolio See the ranking
152
Total patents granted
12
CPC technology areas
24.2
Avg claims per patent
-15%
5-year filing velocity

The verdict

Nevro holds 152 US patents across 12 technology areas, rank #2,564 of 50,000 tracked assignees.

#2,564
of 50,000 US assignees by volume
Top 15%
by Innovation Score (49.3/100)
24.2
avg claims per patent
-15%
filing velocity, last 5 yrs

Portfolio overview

Nevro Corp. has been granted 152 US utility patents between 2015 and 2025, placing Nevro Corp. at rank #2,564 across all assignees tracked by PlainPatent. This portfolio spans 12 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.2 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a US Corporation, Nevro Corp. is one of the more focused assignees in the PatentsView dataset. By volume, Nevro sits between Mitsui Kinzoku ACT Corporation (152 patents, rank #2,560) and The Urban Electric Company (152 patents, rank #2,568) - the closest US assignees by grant volume. The composite Innovation Score of 49.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 70 grants, compared with 82 in the 2015–2019 window, a -15% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Nevro Corp.'s 24.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 12 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Nevro Corp. against peers pursuing similar technology classes.

Who files at Nevro's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Nevro holds 152 patents at rank #2,564, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Nevro

By rank, the assignees closest to #2,564 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Nevro's primary technology class.

Nevro's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

49 Top 15% higher than 85% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

51015202530 20152016201720182019202020212022202320242025 11
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Nevro Corp. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 12 7.9%
2016 27 17.8%
2017 11 7.2%
2018 11 7.2%
2019 21 13.8%
2020 11 7.2%
2021 13 8.6%
2022 13 8.6%
2023 13 8.6%
2024 9 5.9%
2025 11 7.2%

Which technologies does Nevro Corp. patent most?

Top 12 of 12 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Complex
Velocity Declining

Where it ranks

Overall rank by patents

#2,564

Across all tracked assignees

Innovation Score

49.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Nevro Corp. hold?
Nevro Corp. holds 152 US granted patents filed between 2015 and 2025, spanning 12 technology areas.
What is Nevro Corp.'s Innovation Score?
Nevro Corp. has an Innovation Score of 49.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Nevro Corp. focus on?
Nevro Corp.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 147 patents. The company has filed patents in 12 CPC subclasses total.
Is Nevro Corp.'s patent filing rate increasing or decreasing?
Nevro Corp.'s recent filing velocity is -15% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Nevro Corp.'s patents?
Nevro Corp.'s patents average 24.2 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Nevro Corp. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Nevro's 152 grants land it in the top 15% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Nevro ranks #2,564 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61N - see who else leads that technology area. A61N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.